Singer, CF; Egle, D; Greil, R; Ohler, L; Petru, E; Suppan, C; Marhold, M; Pfeiler, G; Brunner, C; Tinchon, C; Halper, S; Galid, A; Pluschnig, U; Haslbauer, F; Hubalek, M; Redl, A; Flatschacher, J; Hennebelle, M; Mraz, B; Bartsch, R.
REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC).
ANN ONCOL. 2020; 31: S77-S78.-ESMO Breast Cancer Virtual Meeting; MAY 23-24, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.03.272
[Oral Communication]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG